A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms CLEAR Outcomes; CVOT
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 20 Mar 2017 According to an Esperion Therapeutics media release, this trial is on track to be well-underway by 1H 2019.
    • 20 Mar 2017 According to an Esperion Therapeutics media release, based on the successful completion of this trial company intends to submit an NDA for a cardiovascular disease risk reduction indication to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) by 2022.
    • 12 Dec 2016 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top